Mutations in the Coding Region of C-myc Occur Frequently in Acquired Immunodeficiency Syndrome-associated Lymphomas
Overview
Affiliations
We have analyzed 30 cases of high- and intermediate-grade acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma (AIDS-NHL) for mutations in the c-myc coding region. In addition, in these same tumors, we have sought the presence of mutations in a regulatory region within the first c-myc intron defined by the binding to a factor that inhibits c-myc transcription (MYC intron factor, or mif). Mutations in the c-myc coding region were present in 10 of 16 small noncleaved cell lymphoma (SNCL), but in only 3 of 14 other histologic subtypes tested (0/3 large non-cleaved cell, 2/8 immunoblastic, and 1/3 anaplastic large cell lymphomas). Nineteen of the AIDS-NHLs analyzed contained a c-myc rearrangement and in 10 of these the c-myc gene was mutated in its coding region. In contrast, we could detect a mutation in the coding region in only 2 of 8 AIDS-NHL without a c-myc rearrangement. Mutations in the mif region were detected in 5 of 16 SNCL. Among AIDS-NHL carrying mutations in the c-myc coding region, only 4 carried mutations in the regulatory region. These results suggest that the mutations in the coding region of the c-myc protein may either be a consequence of the translocations involving c-myc, or may be necessary only in tumors where c-myc is deregulated as a result of a c-myc/lg translocation.
A germline point mutation in the MYC-FBW7 phosphodegron initiates hematopoietic malignancies.
Freie B, Carroll P, Varnum-Finney B, Ramsey E, Ramani V, Bernstein I Genes Dev. 2024; 38(5-6):253-272.
PMID: 38565249 PMC: 11065175. DOI: 10.1101/gad.351292.123.
Luminescence complementation technology for the identification of MYC:TRRAP inhibitors.
Feris E, Hinds J, Cole M Oncotarget. 2021; 12(21):2147-2157.
PMID: 34676047 PMC: 8522838. DOI: 10.18632/oncotarget.28078.
CRY2 and FBXL3 Cooperatively Degrade c-MYC.
Huber A, Papp S, Chan A, Henriksson E, Jordan S, Kriebs A Mol Cell. 2016; 64(4):774-789.
PMID: 27840026 PMC: 5123859. DOI: 10.1016/j.molcel.2016.10.012.
Expression profiling of rectal tumors defines response to neoadjuvant treatment related genes.
Palma P, Cano C, Conde-Muino R, Comino A, Bueno P, Ferron J PLoS One. 2014; 9(11):e112189.
PMID: 25380052 PMC: 4224421. DOI: 10.1371/journal.pone.0112189.
A common functional consequence of tumor-derived mutations within c-MYC.
Chakraborty A, Scuoppo C, Dey S, Thomas L, Lorey S, Lowe S Oncogene. 2014; 34(18):2406-9.
PMID: 24998853 PMC: 4286529. DOI: 10.1038/onc.2014.186.